Clinical Trial
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
- NCT ID
- NCT07161193
- Status
- Not yet recruiting
- Study Type
- Interventional
- Lead Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
- Enrollment
- 30 participants
- Start
- Sep 2025
- Estimated Completion
- Nov 2027
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans
Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.
© 2026 Health AI Central. All rights reserved.
Source: https://healthaicentral.com/research/science-discovery/trials/NCT07161193